PeptideScanner retained ClinicalTrials.gov record NCT00823004 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-12-23, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00008073 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-12-19, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02012556 at 2026-07-30T21:55:56.632Z. Its registry update date was 2013-12-16, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00000400 at 2026-07-30T21:55:56.630Z. Its registry update date was 2013-12-09, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00111566 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-11-28, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00546728 at 2026-07-30T21:55:56.615Z. Its registry update date was 2013-11-08, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01863134 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-10-31, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT01167426 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-10-17, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01394341 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-10-09, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01071083 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-09-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01059461 at 2026-11-16T17:33:14.861Z. Its registry update date was 2013-09-13, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT00119691 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-09-12, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00842023 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-08-30, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01911468 at 2026-07-30T21:55:56.619Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00690430 at 2026-07-30T21:55:56.629Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00942149 at 2026-11-15T22:01:45.056Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01899430 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00826228 at 2026-07-30T21:55:56.618Z. Its registry update date was 2013-07-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01895296 at 2026-11-15T22:05:38.400Z. Its registry update date was 2013-07-10, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00429494 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00311636 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-06-26, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00003394 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01063504 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-06-19, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01215513 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-05-22, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01732068 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01732094 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-05-09, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT01469351 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-04-19, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00927186 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-04-04, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01382589 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-03-22, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT01430195 at 2026-07-30T21:55:56.618Z. Its registry update date was 2013-03-22, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT00451958 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-03-21, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01286051 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-03-20, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00475852 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00597584 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01561066 at 2026-07-30T21:55:56.621Z. Its registry update date was 2013-02-26, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00597753 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00598273 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT00598442 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01071915 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01700478 at 2026-11-15T22:08:31.832Z. Its registry update date was 2013-02-11, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00730015 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-01-30, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT00738673 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-18, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01430104 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-01-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01764230 at 2026-11-15T21:49:16.513Z. Its registry update date was 2013-01-09, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00967018 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-03, and PeptideScanner's reviewed identity mapping was degarelix.